|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.00 EUR | -0.36% |
|
+2.12% | +9.90% |
| 06-23 | Orion's Investigational Drug Wins EU Orphan Drug Designation to Treat Malignant Mesothelioma | MT |
| 06-16 | Digia Unit to Provide Data Integration, AI Analytics for Finnish Health Sector Project | MT |
Company Valuation: Orion Oyj
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,119 | 7,179 | 5,509 | 6,005 | 8,944 | 9,894 | - | - |
| Change | - | 40.25% | -23.26% | 8.99% | 48.95% | 10.62% | - | - |
| Enterprise Value (EV) 1 | 5,010 | 7,060 | 5,603 | 6,126 | 9,088 | 9,794 | 9,582 | 9,327 |
| Change | - | 40.91% | -20.65% | 9.35% | 48.35% | 7.76% | -2.17% | -2.65% |
| P/E | 26.5x | 20.6x | 25.5x | 18.2x | 17.9x | 18x | 15.2x | 13.7x |
| PBR | 6.86x | 7.91x | 6.19x | 5.98x | 6.97x | 6.21x | 5.02x | 4.15x |
| PEG | - | 0.3x | -0.7x | 0.3x | 0.3x | 1.85x | 0.8x | 1.2x |
| Capitalization / Revenue | 4.92x | 5.36x | 4.63x | 3.89x | 4.73x | 4.76x | 4.21x | 3.9x |
| EV / Revenue | 4.81x | 5.27x | 4.71x | 3.97x | 4.81x | 4.71x | 4.07x | 3.68x |
| EV / EBITDA | 17.3x | 14.5x | 17.2x | 12x | 13.2x | 13x | 10.8x | 9.57x |
| EV / EBIT | 20.6x | 16.1x | 20.4x | 14.7x | 14.4x | 14.2x | 11.8x | 10.3x |
| EV / FCF | 38.5x | 21.7x | 105x | 29.7x | 41.5x | 20.3x | 19.1x | 15.3x |
| FCF Yield | 2.6% | 4.6% | 0.95% | 3.37% | 2.41% | 4.93% | 5.24% | 6.53% |
| Dividend per Share 2 | 1.5 | 1.6 | 1.62 | 1.64 | 1.8 | 1.907 | 2.113 | 2.358 |
| Rate of return | 4.11% | 3.12% | 4.13% | 3.83% | 2.83% | 2.71% | 3.01% | 3.36% |
| EPS 2 | 1.38 | 2.49 | 1.54 | 2.35 | 3.56 | 3.907 | 4.612 | 5.14 |
| Distribution rate | 109% | 64.3% | 105% | 69.8% | 50.6% | 48.8% | 45.8% | 45.9% |
| Net sales 1 | 1,041 | 1,341 | 1,190 | 1,542 | 1,890 | 2,080 | 2,352 | 2,537 |
| EBITDA 1 | 289.1 | 487.1 | 326.4 | 509.4 | 688.3 | 752 | 883.9 | 974.2 |
| EBIT 1 | 243.3 | 439.6 | 274.9 | 416.6 | 631.6 | 689 | 814.5 | 905.5 |
| Net income 1 | 193.8 | 349.5 | 216.8 | 329.9 | 500.3 | 549.5 | 649.2 | 724.1 |
| Net Debt 1 | -108.3 | -118.7 | 93.3 | 121.7 | 144.4 | -100.6 | -312.7 | -567.1 |
| Reference price 2 | 36.52 | 51.24 | 39.27 | 42.78 | 63.65 | 70.25 | 70.25 | 70.25 |
| Nbr of stocks (in thousands) | 140,563 | 140,202 | 140,351 | 140,501 | 140,693 | 140,866 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/13/24 | 2/25/25 | 2/12/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.98x | 4.71x | 13.02x | 2.71% | 11.26B | |
| 32.86x | 12x | 24.39x | 0.61% | 1,006B | |
| 26.17x | 6.03x | 16.39x | 2.18% | 589B | |
| 30.87x | 7.21x | 14.74x | 2.85% | 430B | |
| 17.87x | 4.45x | 10.93x | 2.99% | 331B | |
| 23.29x | 4.86x | 13.76x | 1.8% | 288B | |
| 21.56x | 5.56x | 13.49x | 2.84% | 285B | |
| 13.98x | 5.17x | 10.65x | 3.6% | 213B | |
| 22.94x | 6.13x | 10.71x | 2.86% | 190B | |
| -44.37x | 5.36x | 29.56x | 2.62% | 154B | |
| Average | 16.31x | 6.15x | 15.76x | 2.5% | 349.7B | |
| Weighted average by Cap. | 23.23x | 7.52x | 17.43x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORNBV Stock
- Valuation Orion Oyj
Select your edition
All financial news and data tailored to specific country editions
